A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
Open Access
- 14 June 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 119 (24), 5697-5705
- https://doi.org/10.1182/blood-2012-01-405365
Abstract
Clinical-grade T cells are genetically modified ex vivo to express a chimeric antigen receptor (CAR) to redirect specificity to a tumor associated antigen (TAA) thereby conferring antitumor activity in vivo. T cells expressing a CD19-specific CAR recognize B-cell malignancies in multiple recipients independent of major histocompatibility complex (MHC) because the specificity domains are cloned from the variable chains of a CD19 monoclonal antibody. We now report a major step toward eliminating the need to generate patient-specific T cells by generating universal allogeneic TAA-specific T cells from one donor that might be administered to multiple recipients. This was achieved by genetically editing CD19-specific CAR+ T cells to eliminate expression of the endogenous αβ T-cell receptor (TCR) to prevent a graft-versus-host response without compromising CAR-dependent effector functions. Genetically modified T cells were generated using the Sleeping Beauty system to stably introduce the CD19-specific CAR with subsequent permanent deletion of α or β TCR chains with designer zinc finger nucleases. We show that these engineered T cells display the expected property of having redirected specificity for CD19 without responding to TCR stimulation. CAR+TCRneg T cells of this type may potentially have efficacy as an off-the-shelf therapy for investigational treatment of B-lineage malignancies.Keywords
This publication has 50 references indexed in Scilit:
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- Mutation in the TCRα subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRαβ+ T cellsJCI Insight, 2011
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010
- Translating Sleeping Beauty transposition into cellular therapies: Victories and challengesBioEssays, 2010
- Transient cold shock enhances zinc-finger nuclease–mediated gene disruptionNature Methods, 2010
- Enhanced antilymphoma efficacy of CD19-redirected influenza MP1–specific CTLs by cotransfer of T cells modified to present influenza MP1Blood, 2005
- Molecules and mechanisms of the graft-versus-leukaemia effectNature Reviews Cancer, 2004
- Rapid, high-throughput engineering of sequence-specific zinc finger DNA-binding proteinsMethods in Enzymology, 2001
- HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-LeukemiaScience, 1997
- Human T-cell receptor variable gene segment familiesImmunogenetics, 1995